Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 6/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.42 |
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.40 |
| ▸ | USP2 | O75604 | 3/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1684835 | 0.90 | CYP1A2 (0.42) | CYP1A2CYP2D6CYP3A4TSHRCYP2C19 | |
| SCHEMBL1684828 | 0.90 | CYP1A2 (0.42) | CYP1A2CYP2D6CYP3A4TSHRCYP2C19 | |
| SCHEMBL12239007 | 0.86 | CRBN (0.38) | CYP1A2CYP2D6CYP3A4TSHRCYP2C19 | |
| SCHEMBL12238991 | 0.84 | MEN1 (0.39) | CYP2D6TSHRUSP2ALDH1A1OPRD1 | |
| SCHEMBL12238997 | 0.82 | L3MBTL1 (0.42) | CYP1A2CYP2D6CYP3A4TSHRCYP2C19 | |
| SCHEMBL12239014 | 0.81 | CYP3A4 (0.40) | CYP1A2CYP2D6CYP3A4TSHRCYP2C19 | |
| SCHEMBL12238793 | 0.81 | ALDH1A1 (0.37) | CYP2D6ALDH1A1POLB | |
| SCHEMBL12239217 | 0.81 | HTR1A (0.34) | TSHROPRD1OPRK1 | |
| SCHEMBL12239050 | 0.80 | TSHR (0.31) | TSHR | |
| SCHEMBL12302393 | 0.80 | ACACB (0.33) | CYP1A2CYP2D6CYP3A4CYP2C19HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8039472-B2 | Pyrazine-2-carboxamide derivatives to treat diseases mediated by blockade of the epithelial sodium channel | NOVARTIS AG (CH) | 2011-10-18 | — | — | US | disclosed |
| US-20100130506-A1 | Organic Compounds | NOVARTIS AG | 2010-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130506-A1 | Organic Compounds | OR10J3, REN, CACNA1E | CYP1A2 1786/4885CYP2D6 1217/4885CYP3A4 988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.